Cargando…

Malignancies among newly diagnosed systemic lupus erythematosus patients and their survival

The objective of this study was to evaluate the incidence of malignancies among newly diagnosed systemic lupus erythematosus (SLE) patients compared to reference individuals. Another aim was to assess the survival of SLE patients with malignancy compared to references with malignancy. Finnish adult...

Descripción completa

Detalles Bibliográficos
Autores principales: Kariniemi, Simo, Rantalaiho, Vappu, Virta, Lauri J, Kautiainen, Hannu, Puolakka, Kari, Elfving, Pia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709542/
https://www.ncbi.nlm.nih.gov/pubmed/36200539
http://dx.doi.org/10.1177/09612033221131501
_version_ 1784841179883372544
author Kariniemi, Simo
Rantalaiho, Vappu
Virta, Lauri J
Kautiainen, Hannu
Puolakka, Kari
Elfving, Pia
author_facet Kariniemi, Simo
Rantalaiho, Vappu
Virta, Lauri J
Kautiainen, Hannu
Puolakka, Kari
Elfving, Pia
author_sort Kariniemi, Simo
collection PubMed
description The objective of this study was to evaluate the incidence of malignancies among newly diagnosed systemic lupus erythematosus (SLE) patients compared to reference individuals. Another aim was to assess the survival of SLE patients with malignancy compared to references with malignancy. Finnish adult (>17 years) newly diagnosed SLE patients were identified by their drug reimbursement decisions made during 1.1.2000–31.12.2014 from the register of the Social Insurance Institution. For each case, three population controls were individually selected by age, sex and place of residence. Overall, 1006 SLE patients (women 84%), with a mean age of 45.5 years (SD 16 years) and 3005 population controls were linked to Finnish Cancer Registry, and the information about incident malignancies was retrieved from the day the special reimbursement decision for SLE medication was accepted (index day, ID) until 31.12.2018 or until death. The patients diagnosed with malignancy were followed up until 31.12.2019 considering survival. During the follow-up, 85 SLE patients (women 78%) and 192 controls (women 78%) had developed one or more malignancy after the ID. The incidence rate ratio for any malignancy was 1.41 (95% CI 1.08–1.85). The most common malignancy in SLE patients was non-Hodgkin lymphoma, with twelve cases. SLE patients with malignancy had a lower adjusted 15-year survival than controls with malignancy, 27.1% versus 52.4%, and the adjusted hazard ratio for death was 1.68 (95% CI 1.17–2.43). Our results confirm that SLE patients have a higher risk for overall malignancy. The results also suggest that SLE patients with malignancy have lower survival than their references with malignancy.
format Online
Article
Text
id pubmed-9709542
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-97095422022-12-01 Malignancies among newly diagnosed systemic lupus erythematosus patients and their survival Kariniemi, Simo Rantalaiho, Vappu Virta, Lauri J Kautiainen, Hannu Puolakka, Kari Elfving, Pia Lupus Papers The objective of this study was to evaluate the incidence of malignancies among newly diagnosed systemic lupus erythematosus (SLE) patients compared to reference individuals. Another aim was to assess the survival of SLE patients with malignancy compared to references with malignancy. Finnish adult (>17 years) newly diagnosed SLE patients were identified by their drug reimbursement decisions made during 1.1.2000–31.12.2014 from the register of the Social Insurance Institution. For each case, three population controls were individually selected by age, sex and place of residence. Overall, 1006 SLE patients (women 84%), with a mean age of 45.5 years (SD 16 years) and 3005 population controls were linked to Finnish Cancer Registry, and the information about incident malignancies was retrieved from the day the special reimbursement decision for SLE medication was accepted (index day, ID) until 31.12.2018 or until death. The patients diagnosed with malignancy were followed up until 31.12.2019 considering survival. During the follow-up, 85 SLE patients (women 78%) and 192 controls (women 78%) had developed one or more malignancy after the ID. The incidence rate ratio for any malignancy was 1.41 (95% CI 1.08–1.85). The most common malignancy in SLE patients was non-Hodgkin lymphoma, with twelve cases. SLE patients with malignancy had a lower adjusted 15-year survival than controls with malignancy, 27.1% versus 52.4%, and the adjusted hazard ratio for death was 1.68 (95% CI 1.17–2.43). Our results confirm that SLE patients have a higher risk for overall malignancy. The results also suggest that SLE patients with malignancy have lower survival than their references with malignancy. SAGE Publications 2022-10-06 2022-12 /pmc/articles/PMC9709542/ /pubmed/36200539 http://dx.doi.org/10.1177/09612033221131501 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Papers
Kariniemi, Simo
Rantalaiho, Vappu
Virta, Lauri J
Kautiainen, Hannu
Puolakka, Kari
Elfving, Pia
Malignancies among newly diagnosed systemic lupus erythematosus patients and their survival
title Malignancies among newly diagnosed systemic lupus erythematosus patients and their survival
title_full Malignancies among newly diagnosed systemic lupus erythematosus patients and their survival
title_fullStr Malignancies among newly diagnosed systemic lupus erythematosus patients and their survival
title_full_unstemmed Malignancies among newly diagnosed systemic lupus erythematosus patients and their survival
title_short Malignancies among newly diagnosed systemic lupus erythematosus patients and their survival
title_sort malignancies among newly diagnosed systemic lupus erythematosus patients and their survival
topic Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709542/
https://www.ncbi.nlm.nih.gov/pubmed/36200539
http://dx.doi.org/10.1177/09612033221131501
work_keys_str_mv AT kariniemisimo malignanciesamongnewlydiagnosedsystemiclupuserythematosuspatientsandtheirsurvival
AT rantalaihovappu malignanciesamongnewlydiagnosedsystemiclupuserythematosuspatientsandtheirsurvival
AT virtalaurij malignanciesamongnewlydiagnosedsystemiclupuserythematosuspatientsandtheirsurvival
AT kautiainenhannu malignanciesamongnewlydiagnosedsystemiclupuserythematosuspatientsandtheirsurvival
AT puolakkakari malignanciesamongnewlydiagnosedsystemiclupuserythematosuspatientsandtheirsurvival
AT elfvingpia malignanciesamongnewlydiagnosedsystemiclupuserythematosuspatientsandtheirsurvival